Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
55 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Down Syndrome - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Down Syndrome - Pipeline Review, H1 2015', provides an overview of the Down Syndrome's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Down Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Down Syndrome and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Down Syndrome - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Down Syndrome and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Down Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Down Syndrome pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Down Syndrome - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Down Syndrome pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Down Syndrome Overview 7 Therapeutics Development 8 Pipeline Products for Down Syndrome - Overview 8 Pipeline Products for Down Syndrome - Comparative Analysis 9 Down Syndrome - Therapeutics under Development by Companies 10 Down Syndrome - Therapeutics under Investigation by Universities/Institutes 11 Down Syndrome - Pipeline Products Glance 12 Clinical Stage Products 12 Early Stage Products 13 Unknown Stage Products 14 Down Syndrome - Products under Development by Companies 15 Down Syndrome - Products under Investigation by Universities/Institutes 16 Down Syndrome - Companies Involved in Therapeutics Development 17 AC Immune SA 17 Eisai Co., Ltd. 18 F. Hoffmann-La Roche Ltd. 19 NeuroNascent, Inc. 20 Transition Therapeutics Inc. 21 Down Syndrome - Therapeutics Assessment 22 Assessment by Monotherapy Products 22 Assessment by Target 23 Assessment by Mechanism of Action 25 Assessment by Route of Administration 27 Assessment by Molecule Type 29 Drug Profiles 31 ACI-24 - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 APH-1104 - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 AVL-8168 - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 BTD-001 - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 donepezil hydrochloride - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 ELND-005 - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 minocycline - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 NNI-351 - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 RG-1662 - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Small Molecule DYRK1A Inhibitor for CNS Diseases - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 Small Molecules for Down Syndrome - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 Small Molecules to Inhibit OLIG2 for Down Syndrome - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 Down Syndrome - Recent Pipeline Updates 45 Down Syndrome - Discontinued Products 50 Down Syndrome - Product Development Milestones 51 Featured News & Press Releases 51 Nov 20, 2014: Transition Therapeutics Announces Results from ELND005 Clinical Study in Adults with Down Syndrome 51 Apr 07, 2014: Transition Therapeutics Announces Development Update 51 Sep 04, 2013: Transition Therapeutics Announces Dosing of the First Patient in Phase 2a Study of ELND005 in Down Syndrome 53 Sep 03, 2013: Elan Announces Dosing of First Patient in Phase 2a Trial of ELND005 (Scyllo-inositol) in Down Syndrome 53 Feb 27, 2013: Roche Provides Update On Its Clinical Candidate For Down Syndrome 53 Appendix 54 Methodology 54 Coverage 54 Secondary Research 54 Primary Research 54 Expert Panel Validation 54 Contact Us 54 Disclaimer 55
List of Tables Number of Products under Development for Down Syndrome, H1 2015 8 Number of Products under Development for Down Syndrome - Comparative Analysis, H1 2015 9 Number of Products under Development by Companies, H1 2015 10 Number of Products under Investigation by Universities/Institutes, H1 2015 11 Comparative Analysis by Clinical Stage Development, H1 2015 12 Comparative Analysis by Early Stage Development, H1 2015 13 Comparative Analysis by Unknown Stage Development, H1 2015 14 Products under Development by Companies, H1 2015 15 Products under Investigation by Universities/Institutes, H1 2015 16 Down Syndrome - Pipeline by AC Immune SA, H1 2015 17 Down Syndrome - Pipeline by Eisai Co., Ltd., H1 2015 18 Down Syndrome - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 19 Down Syndrome - Pipeline by NeuroNascent, Inc., H1 2015 20 Down Syndrome - Pipeline by Transition Therapeutics Inc., H1 2015 21 Assessment by Monotherapy Products, H1 2015 22 Number of Products by Stage and Target, H1 2015 24 Number of Products by Stage and Mechanism of Action, H1 2015 26 Number of Products by Stage and Route of Administration, H1 2015 28 Number of Products by Stage and Molecule Type, H1 2015 30 Down Syndrome Therapeutics - Recent Pipeline Updates, H1 2015 45 Down Syndrome - Discontinued Products, H1 2015 50
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
